BioSpace3h
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
BioSpace4h
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
BioSpace5h
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
BioSpace6h
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...
BioSpace6h
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
BioSpace7h
The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty
The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...
BioSpace5h
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
BioSpace14h
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
BioSpace14h
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
BioSpace4d
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...
BioSpace4d
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
BioSpace3d
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...